Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.46) by 10.87 percent. This is a 23.88 percent increase over losses of $(0.67) per share from the same period last year. The company reported quarterly sales of $21.000 thousand which missed the analyst consensus estimate of $23.571 thousand by 10.91 percent. This is a 19.23 percent decrease over sales of $26.000 thousand the same period last year.
Allogene Therapeutics Q4 2023 GAAP EPS $(0.51) Misses $(0.46) Estimate, Sales $21.000K Miss $23.571K Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.